Skip to content
The primary complication of endometriosis is a significant reduction in a woman’s quality of life. This includes physical pain, inflammation, gastrointestinal issues, fertility challenges, and psychological struggles. Women may remain unaware of their diagnosis for years, moving from doctor to doctor and treating symptoms. A new blood test, developed by Australian researchers in collaboration with Proteomics International, promises a groundbreaking advance in identifying this chronic condition.
The Global Burden of Endometriosis
Endometriosis is the growth of the uterine lining—endometrium—outside the uterus, where it does not belong. Approximately 190 million women and girls globally suffer from this condition, representing about 10% of all women worldwide.
Even in the absence of symptoms, endometriosis can lead to complications, including heavy menstrual bleeding, painful intercourse, post-coital spotting, digestive issues, and difficulty or inability to conceive. Additionally, the psychological impact is significant: many women with endometriosis experience anxiety and depression.
For more in-depth information on endometriosis, including its causes, symptoms, and treatment, visit the Encyclopedia section of our site.
While there is no cure for endometriosis, a comprehensive treatment approach can restore quality of life and joy. However, identifying the disease remains a major hurdle, with diagnosis taking an average of up to 10 years.
Currently, it takes on average seven years for a woman to receive a diagnosis and during that time she is enduring significant life impacting symptoms, her years of fertility are reducing, and the endometriosis is spreading.
Professor Peter Rogers, Research Director at the Royal Women’s Hospital and at the University of Melbourne
A Breakthrough in Diagnosing Endometriosis
Researchers analyzed plasma samples from over 800 participants, identifying 10 protein biomarkers specific to endometriosis. These biomarkers, or “fingerprints,” form the basis of the PromarkerEndo test. This blood test has demonstrated excellent results in detecting even the early stages of endometriosis.
A blood test is more cost-effective for patients and the health system than the current use of ultrasounds, invasive laparoscopies, MRI’s and biopsies to diagnose endometriosis.
Dr Richard Lipscombe, Managing Director, Proteomics International Laboratories Ltd
The new test is expected to significantly reduce the time and costs associated with diagnostics, providing women with a faster path to relief.
Early Detection: The Key to Effective Treatment
Although no cure exists for endometriosis, early diagnosis can greatly enhance treatment outcomes. Detecting the disease in its early stages allows for effective therapies, such as hormonal treatments, which may be less effective in later stages. According to Professor Rogers, access to early diagnosis and appropriate treatment is critical for improving patients’ quality of life and preserving fertility.
Efforts are ongoing to ensure PromarkerEndo’s reliability for widespread clinical application. The success of this test could pave the way for early intervention and help ease the burden of this debilitating disease for millions of women worldwide.
